Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Delayed Quote USD

Daxor Corporation (DXR)

7.53
-0.21
(-2.71%)
At close: May 2 at 4:00:00 PM EDT
7.77
+0.24
+(3.19%)
After hours: May 2 at 4:05:12 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DXR

Recent News: DXR

View More
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
GlobeNewswire 10 days ago
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
GlobeNewswire 15 days ago
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
GlobeNewswire 17 days ago
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
GlobeNewswire 22 days ago
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
GlobeNewswire 30 days ago
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
GlobeNewswire last month
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
GlobeNewswire last month
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
GlobeNewswire last month
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
GlobeNewswire last month
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
GlobeNewswire last month
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
GlobeNewswire 2 months ago
View More